Eli Lilly continues to see strong growth coming from its GLP-1 drugs. The company's current 2025 guidance looks conservative.

We recently published a list of the 12 Best Long-Term Growth Stocks to Buy Now. In this article, we are going to take a look ...

For years, people taking Ozempic or other drugs in the same class for diabetes and weight loss have noticed the medicines don ...

The Janus Henderson Global Life Sciences Fund returned -11.16% and the MSCI World Health Care IndexSM returned -11.40%. Click ...

A new study adds to a growing body of research suggesting a potential link between popular GLP-1 medications like Ozempic and vision loss.

The results add to evidence from animal studies and reports that people are finding the drugs helpful to manage cravings, not ...

GlobalData’s Revati Tatake discussed key trends in biopharma which are set to have an impact in 2025 and beyond.

A small semaglutide trial suggests the medicine's suppression of appetite may extend to alcohol, but larger tests are needed ...

Telehealth company Hims & Hers stirred up controversy by debuting a 2025 Super Bowl ad touting the benefits of its ...

A new study suggests popular weight-loss drugs like Ozempic and Zepbound may be linked to rare eye conditions that could ...

Lexaria Bioscience Corp., a global innovator in drug delivery platforms, provided progress updates on its Phase 1b, 12-week ...